Cases with high ID2 expression had significantly shorter OS than those with low ID2 expression among whole-cohort AML (P<0.001, Figure 3A) and non-M3-AML (P=0.015, Figure 3B). This evidence concerns the gene ID2 and acute myeloid leukemia.